C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 1, 2007, Pages 63-70

  Zhang, Weixian ^a   Kamiya, Hideki ^a   Ekberg, Karin ^b   Wahren, John ^b   Sima, Anders A F ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

BB Wor rats; C peptide; Morphometry; Nerve conduction velocity; Neuropathy

Indexed keywords

C PEPTIDE; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE COURSE; INSULIN BLOOD LEVEL; MALE; MOTOR NERVE CONDUCTION; MYELINATED NERVE; NERVE DEGENERATION; NERVE FIBER; NERVE REGENERATION; NONHUMAN; OSMOTIC PUMP; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; SCORING SYSTEM; SENSORY NERVE CONDUCTION; SURAL NERVE; TREATMENT DURATION;

ANIMALS; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETIC NEUROPATHIES; INFUSION PUMPS; INJECTIONS, SUBCUTANEOUS; MALE; MOTOR NEURONS; NERVE FIBERS; NERVE FIBERS, MYELINATED; NEURAL CONDUCTION; NEURONS, AFFERENT; RATS; RATS, INBRED BB;

EID: 33846489067     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.672     Document Type: Article

References (52)

1. Greene DA, Feldman EL, Stevens MJ, et al. Diabetic neuropathy. In Ellenberg and Rifkin Diabetes Mellitus (5th edn), Porte D Jr, Sherwin RS (eds). Appleton & Lange: Stanford, 1997; 1009-1076.
2. Dyck PJ, Davies JL, Wilson DM, et al. Risk factors for severity of diabetic polyneuropathy: intensive longitudinal assessment of the Rochester Neuropathy Study Cohort. Diabetes Care 1999; 22: 1479-1486.
3. Sugimoto K, Murakawa Y, Sima AAF. Diabetic neuropathy-a continuing enigma. Diabetes Metab Res Rev 2000; 16: 408-433.
4. Sima AAF. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003; 60: 2445-2464.
5. Pfeifer MA, Schumer MP, Gelber DA. Aldose reductase inhibitors: the end of an era or the need for different trial designs? Diabetes 1997; 46(Suppl. 2): 582-589.
6. Ziegler D, Hanefeld M, Ruknau K-J, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid. Diabetes Care 1999; 22: 1296-1301.
7. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid): a two year multi-center randomized double-blind placebo-controlled trial (ALADIN II). Free Radic Res 1999; 31: 171-179.
8. The Diabetes Control and Complication Trials Research Group. The effect of intensive treatment of diabetes on development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
9. Sima AAF, Zhang W-X, Sugimoto K, et al. C-peptide prevents and improves chronic type 1 diabetic neuropathy in the BB/Worrat. Diabetologia 2001; 44: 889-897.
10. Zhang W, Yorek M, Pierson CR, et al. Human C-peptide dose dependently prevents early neuropathy in the BB/Wor-rat. Int J Exp Diabetes Res 2001; 2: 187-194.
11. Sima AAF, Zhang W, Li Z-G, et al. Molecular alterations underlie nodal and paranodal degeneration in type 1 diabetic neuropathy and are prevented by C-peptide. Diabetes 2004; 53: 1556-1563.
12. Stevens MJ, Zhang W, Li F, Sima AAF. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor-rats. Am J Physiol 2004; 287: E497-E505.
13. Kamiya H, Zhang W, Sima AAF. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol 2004; 56: 827-835.
14. Johansson BI, Borg K, Fernqvist-Forbes E, et al. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia 1996; 39: 687-695.
15. Ekberg K, Brismar T, Johansson B-L, et al. Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes 2003; 52: 536-541.
16. Johansson B-L, Borg K, Fernqvist-Forbes E, et al. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with type 1 diabetes. Diabet Med 2000; 17: 181-189.
17. Ekberg K, Juntti-Berggren L, Norrby A, et al. C-peptide improves sensory nerve function in type 1 diabetes neuropathy. Diabetologia 2005; 48(Suppl. 1): A81.
18. Mordes JP, Bartell R, Groen H, et al. Autoimmune diabetes mellitus in the BB-rat. In Animal Models of Diabetes, Sima AAF, Shaffir E (eds). Harwood Academic Publishers: Amsterdam, 2001; 1-42.
19. Sima AAF (ed). Chronic Complications in Diabetes: Animal Models and Chronic Complications. Harwood Academic Publishers: Amsterdam, 2000.
20. Polonsky KS, Given BD, Van Canter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 1988; 81: 442-448.
21. +-ATPase activity in synergism with neuropeptide Y. Diabetologia 1996; 39: 199-205.
22. Ido Y, Vindigni A, Chang K, et al. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997; 277: 563-566.
23. Forst T, Kunt T, Pohlmann T, et al. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest 1998; 101: 2036-2041.
24. Jensen ME, Messina EJ. C-peptide induces concentration-dependent dilatation of skeletal muscle arterioles only in the presence of insulin. Am JPhysiol 1999; 276: H1223-H1228.
25. Cotter M, Ekberg K, Wahren J, Cameron N. Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003; 52: 1812-1817.
26. Kitamura T, Kimura K, Makondo K, et al. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia 2003; 46: 1698-1705.
27. Rigler R, Pramanik A, Jonasson P, et al. Specific binding of proinsulin C-peptide to human membranes. Proc Natl Acad Sci USA 1999; 96: 1318-1323.
28. Grunberger G, Qiang X, Li Z-G, et al. Molecular basis for the insulinomimetic effects of C-peptide. Diabetologia 2001; 44: 1247-1257.
29. Zhong Z, Davidescu A, Ehrén I, et al. C-peptide stimulates ERK1/2 and JNK MAP-kinases via activation of PKC in human renal tubular cells. Diabetelogia 2005; 48: 187-197.
30. Sima AAF, Blaivas M. Peripheral neuropathies. In Neuropathology, the Diagnostic Approach, Garcia JH, Budka H, Mckeever PE, Sarnat HB, Sima AAF (eds). Mosby: St Louis, 1997; 765-809.
31. Pierson CR, Zhang W, Sima AAF. Proinsulin C-peptide replacement in type 1 diabetic BB/Wor-rats prevents deficits in nerve fiber regeneration. J Neuropathol Exp Neurol 2003; 62: 765-779.
32. Li Z-G, Zhang W, Sima AAF. C-peptide enhances insulin-mediated cell growth and protection against high-glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev 2003; 19: 375-385.
33. Grunberger G, Sima AAF. The C-peptide signaling. Exp Diabesity Res 2004; 5: 25-36.
34. Sima AAF, Kamiya H. Insulin, C-peptide and diabetic neuropathy. Science Med 2004; 10: 308-319.
35. Brismar T, Sima AAF, Greene DA. Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol 1987; 21: 504-507.
36. Sima AAF, Brismar T. Reversible diabetic nerve dysfunction. Structural correlates to electrophysiological abnormalities. Ann Neurol 1985; 18: 21-29.
37. Sima AAF. Diabetes underlies common neurological disorders. Ann Neurol 2004; 56: 459-461.
38. Sima AAF, Lattimer SA, Yagihashi S, Greene DA. "Axo-glial dysjunction" a novel structural lesion that accounts for poorly reversible slowing of nerve conduction in the spontaneously diabetic BB-rat. J Clin Invest 1986; 77: 474-484.
39. Sima AAF, Cherian PV. Neuropathology of diabetic neuropathy and its correlations with neurophysiology, J Clin Neruoscience 1997; 4: 359-364.
40. Hoffman PN, Cleveland DW, Griffin JW, et al. Neurofilament gene expression: a major determinant of axonal caliber. Proc Natl Acad Sci USA 1987; 84: 3472-3476.
41. Scott JN, Clark AW, Zochodne DW. Neurofilament and tubulin gene expression in progressive experimental diabetes: Failure of synthesis and export by sensory neurons. Brain 1999; 122: 2109-2117.
42. Zochodne DW. Neurotrophins and other growth factors in diabetic neuropathy. Semin Neurol 1996; 16: 153-161.
43. Ishii DN, Lupien SB. Insulin-like growth factors protect against diabetic neuropathy: effects on sensory nerve regeneration in rats. J Neurosci Res 1995; 40: 138-144.
44. Tomlinson DR, Fernyhough P, Diemel LT. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factor. Diabetes 1997; 46(Suppl. 2): S43-S49.
45. Sayers NM, Beswick LJ, Middlemas A, et al. Neurotrophin-3 prevents the proximal accumulation of neurofilament proteins in sensory neurons of streptozotocin-induced diabetic rats. Diabetes 2003; 52: 2372-2380.
46. Xu G, Murakawa Y, Pierson CR, Sima AAF. Altered ß-tubulin and neurofilament expression and impaired axonal growth in diabetic nerve regeneration. J Neuropathol Exp Neurol 2002; 61: 164-175.
47. Tomlinson DR, Fernyhough P. Neurotrophism in diabetic neuropathy. In Chronic Complications in Diabetes. Frontiers in Animal Diabetes Research, Sima AAF (ed). Harwood Academic Publishers: Amsterdam, 2000; 167-182.
48. Reico-Pinto E, Rechler MM, Ishii DN. Effects of insulin, insulin-like growth factor II, and nerve growth factor on neurite formation and survival of cultured sympathetic and sensory neurons. J Neurosci 1986; 6: 1211-1219.
49. Sima AAF. Trophic factors and inflammatory mediators in diabetic complications. Exp Diabesity Res 2003; 4: 203-312.
50. Pierson CR, Zhang W, Murakawa Y, Sima AAF. Early gene responses of trophic factors differ in nerve regeneration in type 1 and type 2 diabetic neuropathy. J Neuropathol Exp Neurol 2002; 61: 857-871.
51. Kamiya H, Murakawa Y, Zhang W, Sima AAF. Sensory nociceptive neuropathy differs in type 1 and type 2 diabetes. Diabetes Metab Res Rev 2005; 21: 448-458.
52. Brussee V, Cunningham FA, Zochodne DW. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 2004; 53: 1824-1830.